GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding GRI Bio, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 8 | 5 | −3 |
| SharesConverted for a 1-for-17 split | 13.2K | 4.85K | −8.32K (−63.2%) |
| Value | $185.2K | $15.5K | −$169.7K (−91.6%) |
New holders (0)
Institutions that held GRI Bio, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
None.
Sold out (3)
Institutions that held GRI Bio, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Geode Capital Management, LLC | 76,182 | $63.1K |
| Virtu Financial LLC | 30,381 | $25.0K |
| Two Sigma Securities, LLC | 15,861 | $13.1K |